1
40
2
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Treatment of Symptoms in Children with Q3 Conditions Scoping Review Results
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1006/mgme.1999.2815" target="_blank" rel="noreferrer noopener">http://doi.org/10.1006/mgme.1999.2815</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Melatonin ineffective in neuronal ceroid lipofuscinosis patients with fragmented or normal motor activity rhythms recorded by wrist actigraphy
Publisher
An entity responsible for making the resource available
Molecular Genetics and Metabolism
Date
A point or period of time associated with an event in the lifecycle of the resource
1999
Subject
The topic of the resource
Adolescent; Adult; Antioxidants/tu [Therapeutic Use]; Child; Circadian Rhythm; Dose-Response Relationship; Drug Electrophysiology; Female; Humans; Male; Melatonin/tu [Therapeutic Use]; Neuronal Ceroid-Lipofuscinoses/dt [Drug Therapy]; Sleep Wake Disorders/th [Therapy]; 0 (Antioxidants); JL5DK93RCL (Melatonin); sleep disturbance/disorders; NCL3; pharmacologic intervention; melatonin
Creator
An entity primarily responsible for making the resource
Hätönen T; Kirveskari E; Heiskala H; Sainio K; Laakso M L; Santavuori P
Description
An account of the resource
Melatonin was tested as a sleeping pill in five patients with neuronal ceroid lipofuscinoses. The single-blind, placebo-controlled study consisted of motor activity recordings, sleep logs, and administration of placebo or melatonin (2.5 or 5 mg). Daily motor activity rhythms were measured by wrist actigraphy during four 7-day periods (baseline, placebo, melatonin 2.5 mg, and melatonin 5 mg). The placebo or melatonin was administered in the evenings for 3 weeks, and the recordings were made during the last week of the 3-week treatment. Sleep logs were kept by the caregivers during the recordings. Based on period analyses, the activity recordings were evaluated to display a normal (24-h) or fragmented rhythm. Three patients had normal motor activity patterns during the baseline recordings, and administration of placebo or melatonin did not affect their rest/activity rhythms. Two patients had abnormally fragmented activity rhythms during the baseline periods, and administration of placebo or melatonin did not induce synchronization. According to the actigraphic data, there were no changes in activity rhythms resulting from administration of melatonin. However, based on the observations, three families reported that melatonin slightly improved the sleep quality of the patients. These controversial findings show the difficulties involved in specifying the role of melatonin in modulating sleep. Thus, we conclude that more evidence is required before the significance of melatonin as a sleeping pill is defined.Copyright 1999 Academic Press.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1006/mgme.1999.2815" target="_blank" rel="noreferrer noopener">10.1006/mgme.1999.2815</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
0 (Antioxidants)
1999
Adolescent
Adult
Antioxidants/tu [Therapeutic Use]
Child
Circadian Rhythm
Dose-Response Relationship
Drug Electrophysiology
Female
Hätönen T
Heiskala H
Humans
JL5DK93RCL (Melatonin)
Kirveskari E
Laakso M L
Male
melatonin
Melatonin/tu [Therapeutic Use]
Molecular Genetics and Metabolism
NCL3
Neuronal Ceroid-Lipofuscinoses/dt [Drug Therapy]
pharmacologic intervention
Sainio K
Santavuori P
sleep disturbance/disorders
Sleep Wake Disorders/th [Therapy]
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1111/j.1600-079x.1996.tb00286.x" target="_blank" rel="noreferrer">http://doi.org/10.1111/j.1600-079x.1996.tb00286.x</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Use of melatonin in the treatment of paediatric sleep disorders
Publisher
An entity responsible for making the resource available
Journal Of Pineal Research
Date
A point or period of time associated with an event in the lifecycle of the resource
1996
Subject
The topic of the resource
Child; Adult; Disabled Persons; Preschool; infant; Chronic disease; Administration; Oral; Human; Adolescence; Melatonin/tu [Therapeutic Use]; Sleep Disorders/dt [Drug Therapy]; Melatonin/ae [Adverse Effects]
Creator
An entity primarily responsible for making the resource
Jan JE; O'Donnell ME
Description
An account of the resource
A group of Vancouver health professionals, including the authors, have studied the use of oral melatonin in the treatment of chronic sleep disorders in children with disabilities since the Fall of 1991. This review article is based on the first 100 patients, half of whom were visually impaired or blind. Children with neurological, neuropsychiatric, and developmental disabilities are predisposed to chronic sleep-wake cycle disturbances. Disorders such as blindness, deaf-blindness, mental retardation, autism, and central nervous system diseases, among others, diminish the ability of these individuals to perceive and interpret the multitude of cues for synchronizing their sleep with the environment. Melatonin, which benefitted slightly over 80% of our patients, appears to be a safe, inexpensive, and a very effective treatment of sleep-wake cycle disorders. The oral dose of fast release melatonin taken at bed-time ranged from 2.5 mg to 10 mg. Side effects or the development of tolerance have not been observed. Since the causes of sleep difficulties are extremely variable, not all children are candidates for treatment. For successful melatonin treatment, clinical experience is required, and the influences of other health problems and medications need to be considered. Further clinical and laboratory research in this field is imperative because melatonin treatment offers enormous health, emotional, social, and economic benefits to society, especially since multidisabled children with chronic sleep difficulties do not respond well to current therapeutic regimes. [References: 61]
1996
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1111/j.1600-079x.1996.tb00286.x" target="_blank" rel="noreferrer">10.1111/j.1600-079x.1996.tb00286.x</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
1996
Administration
Adolescence
Adult
Backlog
Child
Chronic Disease
Disabled Persons
Human
Infant
Jan JE
Journal Article
Journal Of Pineal Research
Melatonin/ae [Adverse Effects]
Melatonin/tu [Therapeutic Use]
O'Donnell ME
Oral
Preschool
Sleep Disorders/dt [Drug Therapy]